Related dementias

Supports Phase 1–3 trials of combination approaches for Alzheimer’s disease and related dementias, with mechanistic rationale and appropriate biomarkers. Phase 1 support is capped at USD 1 million; Phase 2–3 at USD 2 million over two to three years. Exceptional requests up to USD 3 million require case-by-case consideration. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

…leads for Alzheimer’s disease and related dementias. Separate tracks support lead optimization and work enabling an investigational-new-drug submission. Awards are up to USD 1 million over two to three years. Pure algorithm development, general AI platforms, repurposing and clinical trial execution are excluded. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).